About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which serves as sole funder for MPP’s activities in HIV, hepatitis C and tuberculosis.
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to December 2019
Billion doses of treatment supplied to date
Million patient-years of treatment through MPP’s generic partners, from January 2012 to December 2019
For Everyone Everywhere
Discover where we helped and what we have achieved
Key Publications
Annual Reports
15 June 2019
Twitter Feed
MedicinesPatentPool @MedsPatentPool
MPP's ED @CharlieGore: #Diabetes is a serious & potentially life-threatening condition that affects nearly half a billion around the 🌍, of whom 79% live in #LMICs. We look forward to working w/ @IntDiabetesFed to facilitate access to patented life-saving diabetes meds in LMICs. https://t.co/L6Kz7eUdmC
MedicinesPatentPool @MedsPatentPool
📢NEWS: MPP & @IntDiabetesFed join forces to improve access to affordable & high-quality #diabetes medicines 💊. More than 460 million people around the 🌍 are living w/ diabetes & many more are at risk. #AccessToMedicines remains a key barrier. Read on: https://t.co/fE9nCYGy5U https://t.co/Sr2yX08WhF
Mylan @MylanNews
In 2016, we joined the @WHO’s #NOhep goal to eliminate hepatitis by 2030. With plenty of work still to be done, read more about how we work with industry leaders like the @MedsPatentPool to help expand access to treatment. https://t.co/wYFdJgwAV2 #WorldHepatitisDay https://t.co/SNr6DU9Ann